EP2089057A2 - Verfahren und zusammensetzungen zur behandlung und überwachung der behandlung von mit il 13 assoziierten erkrankungen - Google Patents
Verfahren und zusammensetzungen zur behandlung und überwachung der behandlung von mit il 13 assoziierten erkrankungenInfo
- Publication number
- EP2089057A2 EP2089057A2 EP07867722A EP07867722A EP2089057A2 EP 2089057 A2 EP2089057 A2 EP 2089057A2 EP 07867722 A EP07867722 A EP 07867722A EP 07867722 A EP07867722 A EP 07867722A EP 2089057 A2 EP2089057 A2 EP 2089057A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- seq
- antagonist
- antibody
- antibody molecule
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/247—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Food Science & Technology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87433306P | 2006-12-11 | 2006-12-11 | |
US92593207P | 2007-04-23 | 2007-04-23 | |
PCT/US2007/025418 WO2008073463A2 (en) | 2006-12-11 | 2007-12-11 | Methods and compositions for treating and monitoring treatment of il-13-associated disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2089057A2 true EP2089057A2 (de) | 2009-08-19 |
Family
ID=39295599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07867722A Withdrawn EP2089057A2 (de) | 2006-12-11 | 2007-12-11 | Verfahren und zusammensetzungen zur behandlung und überwachung der behandlung von mit il 13 assoziierten erkrankungen |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP2089057A2 (de) |
JP (1) | JP2010512402A (de) |
BR (1) | BRPI0720280A2 (de) |
CA (1) | CA2672215A1 (de) |
MX (1) | MX2009005725A (de) |
RU (1) | RU2009120202A (de) |
WO (1) | WO2008073463A2 (de) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
TW200848429A (en) * | 2007-04-23 | 2008-12-16 | Wyeth Corp | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
CA2734645A1 (en) * | 2008-08-20 | 2010-02-25 | Centocor Ortho Biotech Inc. | Engineered anti-il-13 antibodies, compositions, methods and uses |
GB0904214D0 (en) | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
DE102011006809A1 (de) * | 2011-04-05 | 2012-10-11 | Freistaat Bayern vertreten durch die Julius-Maximilians-Universität Würzburg | Verwendung eines Mittels aus Antikörpern und/oder Insulin-like growth factor-Antagonisten |
US9511150B2 (en) | 2011-07-19 | 2016-12-06 | CellMosaic, Inc. | Crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof |
CN104066451B (zh) * | 2011-07-19 | 2017-04-05 | 希默赛生物技术有限责任公司 | 新交联试剂、大分子、治疗用偶联物及其合成方法 |
EP2747785A4 (de) * | 2011-08-26 | 2015-04-15 | Univ California | Verfahren und zusammensetzungen zur behandlung von atemwegserkrankungen durch nkg2d hemmung |
MA43918A (fr) | 2015-04-14 | 2018-12-05 | Chugai Pharmaceutical Co Ltd | Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31 |
WO2018195388A1 (en) * | 2017-04-21 | 2018-10-25 | Kindred Biosciences, Inc. | Il4/il13 receptor molecule for veterinary use |
WO2019197563A2 (en) * | 2018-04-11 | 2019-10-17 | Enterome S.A. | Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation |
TW202128222A (zh) | 2019-11-20 | 2021-08-01 | 日商中外製藥股份有限公司 | 含有抗體之製劑 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003243189B2 (en) * | 2002-05-01 | 2008-01-24 | Regeneron Pharmaceuticals, Inc. | Methods of using cytokine antagonists to treat HIV infection and AIDS |
US20070048785A1 (en) * | 2004-06-09 | 2007-03-01 | Lin Laura L | Anti-IL-13 antibodies and complexes |
AR049390A1 (es) * | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
-
2007
- 2007-12-11 RU RU2009120202/15A patent/RU2009120202A/ru not_active Application Discontinuation
- 2007-12-11 MX MX2009005725A patent/MX2009005725A/es not_active Application Discontinuation
- 2007-12-11 JP JP2009541364A patent/JP2010512402A/ja not_active Withdrawn
- 2007-12-11 EP EP07867722A patent/EP2089057A2/de not_active Withdrawn
- 2007-12-11 CA CA002672215A patent/CA2672215A1/en not_active Abandoned
- 2007-12-11 WO PCT/US2007/025418 patent/WO2008073463A2/en active Application Filing
- 2007-12-11 BR BRPI0720280-6A patent/BRPI0720280A2/pt not_active IP Right Cessation
Non-Patent Citations (5)
Title |
---|
CETRE C ET AL: "Interleukin-13 and IgE production in rat experimental schistosomiasis", EUROPEAN CYTOKINE NETWORK, JOHN LIBBEY EUROTEXT LTD, FR, vol. 11, no. 2, 1 June 2000 (2000-06-01), pages 241 - 249, XP008090844, ISSN: 1148-5493 * |
HART T K ET AL: "Preclinical efficacy and safety of pascolizumab (SB 240683): A humanized anti-interleukin-4 antibody with therapeutic potential in asthma", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, WILEY-BLACKWELL PUBLISHING LTD, GB, vol. 130, no. 1, 1 October 2002 (2002-10-01), pages 93 - 100, XP002434532, ISSN: 0009-9104, DOI: DOI:10.1046/J.1365-2249.2002.01973.X * |
PERKINS ET AL: "IL-4 induces IL-13-independent allergic airway inflammation", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, MOSBY, INC, US, vol. 118, no. 2, 1 August 2006 (2006-08-01), pages 410 - 419, XP005587359, ISSN: 0091-6749, DOI: DOI:10.1016/J.JACI.2006.06.004 * |
TAUBE CHRISTIAN ET AL: "The role of IL-13 in established allergic airway disease.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 DEC 2002 LNKD- PUBMED:12444158, vol. 169, no. 11, 1 December 2002 (2002-12-01), pages 6482 - 6489, ISSN: 0022-1767 * |
YANG GAOYUN ET AL: "Therapeutic dosing with anti-interleukin-13 monoclonal antibody inhibits asthma progression in mice.", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS APR 2005 LNKD- PUBMED:15644434, vol. 313, no. 1, April 2005 (2005-04-01), pages 8 - 15, XP002644930, ISSN: 0022-3565, DOI: doi:10.1124/jpet.104.076133 * |
Also Published As
Publication number | Publication date |
---|---|
CA2672215A1 (en) | 2008-06-19 |
WO2008073463A2 (en) | 2008-06-19 |
WO2008073463A3 (en) | 2008-10-02 |
JP2010512402A (ja) | 2010-04-22 |
BRPI0720280A2 (pt) | 2014-01-28 |
MX2009005725A (es) | 2009-08-24 |
RU2009120202A (ru) | 2011-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7943342B2 (en) | Nucleic acids encoding IL-13 binding agents | |
US20090098142A1 (en) | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders | |
AU2005327240B2 (en) | IL-13 binding agents | |
US20090068195A1 (en) | Methods and compositions for treating and monitoring treatment of il-13-associated disorders | |
KR101462878B1 (ko) | 사람 인터루킨-13에 대한 항체 및 이의 용도 | |
WO2008073463A2 (en) | Methods and compositions for treating and monitoring treatment of il-13-associated disorders | |
CN101600456A (zh) | 治疗il-13相关疾病和监测il-13相关疾病治疗的方法和组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20090521 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
17Q | First examination report despatched |
Effective date: 20091109 |
|
DAX | Request for extension of the european patent (deleted) | ||
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: WYETH LLC |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20120426 |